All In MedTech

Device Trial Radar · NCT06188936

Home Semen Analysis Tests As a Screening Tool for Fertility Patients

Home Semen Analysis Tests As a Screening Tool for the Initial Assessment of Patients Referred to the Fertility Clinic: Assessing the Feasibility of a Randomised Trial in the UK

Last checked: Nov 19, 2026Latest source record: Jan 20, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

200

Actual

Start

Nov 8, 2023

Primary completion

Feb 1, 2024

Study completion Oct 29, 2024

Sponsor

Lead sponsor
University of AberdeenAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Jan 3, 2024

More device trials from this sponsor

Design

Study type
Interventional
Phase
Early phase 1
Allocation
Non randomized
Model
Sequential
Masking
None
Primary purpose
Diagnostic
FDA-regulated device
No
Who can join
All sexes, from 18 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

Infertility, defined as the inability to conceive after 12 months of regular unprotected intercourse, is estimated to affect 1 in 7 heterosexual couples. Semen analysis, carried out as per the detailed World Health Organisation (WHO) standards in an andrology laboratory, is the primary investigation for the male partner presenting to the fertility clinic and reports on multiple semen parameters. Hospital clinic attendance is required, which could be at a significant distance from the patient's home, to produce a sample at a given appointment time that is then analysed by the laboratory without delay, as the results are time sensitive. A formal report is produced after several weeks. This process was not sustainable during the Covid pandemic and these methods would be threatened by similar situations in the future. Despite semen analysis being an essential component of fertility work-up the WHO themselves state that the test does not distinguish between fertile and infertile men. In addition, it involves a significant cost to the national healthcare system. Therefore, a more efficient initial test of male fertility warrants consideration. Home semen analysis tests are a screening tool that provide a simplified, initial assessment. They are widely available to purchase in the UK, but are not currently issued to patients seen in NHS clinics. They have the potential to reduce time to diagnosis and reduce the cost to the healthcare provider. To investigate the clinical and cost effectiveness of using home semen analysis tests a randomised controlled trial (RCT) is needed comparing them to laboratory semen analysis (standard care). Before a fully-fledged national trial is planned in a UK setting, the investigators would like to undertake a feasibility study to answer, "Is it feasible to conduct a trial comparing home semen analysis tests with current standard practice for the initial assessment of men referred to the fertility clinic?"

Conditions

  • Male Infertility

Interventions

  • ExSeed®Device

    In work package 3, participants will use the provided ExSeed® device and associated app downloaded onto their smartphone to analyse a semen sample provided at home. The app gives a result of "normal" or "below normal," as well as an exact value for sperm concentration, progressive motility, and total motile sperm count. The patient will send their semen analysis results from the smartphone to the research team via secure email.

  • SurveyOther

    Surveys will be completed on a hard copy or electronically.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. What proportion of clinicians are willing to recruit participants to the proposed trial?Time frame: 2 months

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Aberdeen Fertility Centre

    Aberdeen, United Kingdom

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.